Loading...
XNAS
ASMB
Market cap142mUSD
Jul 09, Last price  
18.72USD
1D
3.48%
1Q
121.28%
Jan 2017
-87.16%
IPO
-75.24%
Name

Assembly Biosciences Inc

Chart & Performance

D1W1MN
XNAS:ASMB chart
P/E
—
P/S
5.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.37%
Rev. gr., 5y
12.31%
Revenues
29m
+298.16%
0000000009,018,75014,804,00015,963,00079,105,0006,254,00007,163,00028,520,000
Net income
-40m
L-34.38%
-8,786,430-4,539,405-15,290,625-34,344,730-24,790,430-19,403,759-23,788,799-28,453,833-44,261,562-42,808,548-90,751,000-97,634,000-59,528,000-129,855,000-92,070,000-61,228,000-40,177,000
CFO
-51m
L
-4,147,204-3,483,919-5,214,427-25,068,832-21,379,790-17,796,088-14,973,502-18,697,334-34,881,6551,860,081-64,958,000-84,067,000-62,957,000-93,396,000-84,463,00022,743,000-51,117,000
Earnings
Aug 06, 2025

Profile

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
URL
https://www.assemblybio.com/
IPO date
Dec 17, 2010
Employees
70
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
28,520
298.16%
7,163
 
Cost of revenue
73,940
120,709
94,612
Unusual Expense (Income)
NOPBT
(45,420)
(113,546)
(94,612)
NOPBT Margin
Operating Taxes
330
33
(1,022)
Tax Rate
NOPAT
(45,750)
(113,579)
(93,590)
Net income
(40,177)
-34.38%
(61,228)
-33.50%
(92,070)
-29.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,294
13,689
325
BB yield
Debt
Debt current
461
1,220
3,364
Long-term debt
5,717
3,464
3,566
Deferred revenue
55,379
2,733
Other long-term liabilities
35,378
2,733
Net debt
(105,901)
(125,563)
(84,680)
Cash flow
Cash from operating activities
(51,117)
22,743
(84,463)
CAPEX
(28)
(255)
(102)
Cash from investing activities
40,171
(69,138)
90,640
Cash from financing activities
29,449
13,818
614
FCF
(46,379)
(112,365)
(90,347)
Balance
Cash
112,079
130,247
91,610
Long term investments
Excess cash
110,653
129,889
91,610
Stockholders' equity
(826,129)
(785,824)
(725,274)
Invested Capital
897,955
884,642
816,869
ROIC
ROCE
EV
Common stock shares outstanding
6,005
4,577
4,034
Price
Market cap
EV
EBITDA
(45,291)
(113,096)
(94,114)
EV/EBITDA
Interest
498
Interest/NOPBT